SI
SI
discoversearch

 Biotech / Medical | MultiCell Technologies, Inc.


Previous 10 | Next 10 
To: Shawn Donahue who wrote (18)9/25/2004 2:12:21 AM
From: CENTrader
   of 228
 
Shawn,

Nice to see you around. Whatcha been up to?? Amazing journey, yet she still sits at a pathetic price.

Still Long & Strong,
cT

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (2)


To: CENTrader who wrote (20)9/25/2004 10:43:23 PM
From: RWS
   of 228
 
Average volume has been rising over past eight trading days. If this keeps up for little while there will be an eye-popping reaction in price.

RWS

Share Recommend | Keep | Reply | Mark as Last Read


From: Tradenride10/9/2004 4:08:22 PM
   of 228
 
Re: EAC on RB

immortalmucl, lets keep the pressure on eac. Keep in mind once you start making too much sense he will ignore you. I am surprised he has not ignored you already like dog and me. Remember, he has an agenda. If you look at the last three quarters you will see that cash flow is more instructive because XenoTech is responsible for any costs related to sales. The costs of on going ops have been alleviated due to outsourcing of production, sales and packaging/shipping. This is the result of Jerry's reorganization plan and BTW, general and administrative costs from that reorganization are done. The burn rate has been cut in half if not more and that is why Jerry made the statement in 7/15 10q, "The additional royalties we will now begin to receive from XenoTech may be sufficient to cover our cash requirements for ongoing operations." These are the things eac conveniently avoids because he cannot argue these points. He is very, very selective in his replies and that is why he copies and pastes specific statements from your posts that he can manipulate into a negative outlook for the company. I will post this on SI so he can see I am still making sense.

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: Tradenride who wrote (22)10/11/2004 12:03:02 PM
From: EACarl
   of 228
 
hi trade.......RE" The additional royalties we will now begin to receive from XenoTech may be sufficient to cover our cash requirements for ongoing operations."

It amuses me to no end that this is one of your favorite catch phrases!
"MAY BE" as anyone as intelligent as Coco the monkey will tell you equally implies "may be NOT".

I really hope you have something better to hang your hopes on
than "may be".

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: CENTrader who wrote (20)10/12/2004 2:26:06 PM
From: Shawn Donahue
   of 228
 
MultiCell SAB Taps Scripps Research Institute Immunology Head, Dr. Richard Ulevitch
Tuesday October 12, 12:26 pm ET

[Centrader, nice to see you still following this stock too!
It appears below that our patience may be rewarded in the near future, in my humble opinion. Management seems to have the confidence to bring in those with knowledge, experience, and connections to hopefully help this company expand its potential opportunities to make a real difference for pharmaceutical companies and those that suffer from liver disease, inmo. Thanks for starting this new board. Shawn]

WARWICK, R.I.--(BUSINESS WIRE)--Oct. 12, 2004--MultiCell Technologies, Inc. (MultiCell) (OTCBB:MUCL - News) announced that endotoxin pioneer Richard Ulevitch, Ph.D. has joined the Company's Scientific Advisory Board (SAB). "Dr. Ulevitch is another jewel in the crown of our illustrious Scientific Advisory Board, adding the immunology facet to its current structure," noted Dr. Ron Faris, Senior Vice President, Chief Science Officer and SAB Chairman. The Company's SAB already includes noted scientists Sangeeta Bhatia, M.D., Ph.D.; Douglas Hixson, Ph.D.; Edward Maggio, Ph.D.; Andrew Parkinson, Ph.D.; and Stephen Chang, Ph.D. The SAB guides the company in strategic planning and prioritizes product development and business opportunities.
Dr. Ulevitch is Chairman of the Department of Immunology at The Scripps Research Institute in La Jolla, California. He has advanced the study of the immune system immeasurably by his 30 years of work at Scripps with endotoxins, disease, and the body's tragic response to endotoxins. Ulevitch received his doctorate in biochemistry from the University of Pennsylvania and did post-doctoral training at the University of Minnesota.

"I look forward to helping advance the use of MultiCell's immortalized human hepatocytes as a toxicology screening tool and therapeutic protein manufacturing platform. I am excited by the opportunity the Fa2N4 hepatocyte line may present to help cure liver diseases more cost-effectively," Ulevitch stated.

MultiCell Technologies, Inc. provides non-tumorigenic hepatic (liver) cells and cell lines to pharmaceutical companies for induction studies and toxicity screening for drug discovery. Hepatocytes express drug-metabolizing enzymes that biotransform drugs or substances ingested into the body. Most new drugs fail or are rejected by the FDA due to hepatotoxicity and/or drug-drug interactions; this costs the pharmaceutical industry about $2 billion each year. It costs about $900 million to develop and test a new medicine.

For pricing and delivery information of 6 to 96 well plates or vials, contact MultiCell's marketing and manufacturing licensee, XenoTech, LLC of Lenexa, KS, (913) GET-P450.

MultiCell is also developing biologics for use in diagnostic and therapeutic applications, as well as liver-derived therapeutic proteins which could be used to treat liver-related diseases.

The Company's majority-owned Xenogenics subsidiary owns all rights to the patented Sybiol(TM) synthetic bio-liver device, under development, which is intended to operate optimally with MultiCell's immortalized hepatocytes.

MultiCell's headquarters are at 55 Access Road, Suite 700, Warwick, Rhode Island. For more information about MultiCell and its Xenogenics subsidiary, call 401-738-7560 or see www.multicelltechnologies.com.

The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.



--------------------------------------------------------------------------------
Contact:
MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560



--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.


biz.yahoo.com

Share Recommend | Keep | Reply | Mark as Last Read


From: Shawn Donahue10/19/2004 12:08:44 PM
   of 228
 
MultiCell Gains Japanese Pharma Licensee for Its Proprietary Hepatocytes
Monday October 18, 8:03 am ET


WARWICK, R.I.--(BUSINESS WIRE)--Oct. 18, 2004--Japanese pharmaceutical corporation Eisai Co., Ltd. signed a three-year use and propagation license for MultiCell hepatocytes with Nosan Corporation, an exclusive sub-licensee in Japan of XenoTech, LLC, the exclusive licensee for proprietary hepatocyte cell lines from MultiCell Technologies, Inc. (OTCBB:MUCL - News).
This six-figure ($US) contract allows Eisai to grow and use Fa2N-4 hepatocytes for internal testing purposes at one site. Human liver cells for laboratory use are scarce in Japan, and are invaluable as a predictable indicator for high throughput screening of potential therapeutic compounds for drug discovery.

Eisai Co., Ltd. is a research-based human health care company that discovers, develops and markets products in over thirty countries worldwide. Eisai focuses on areas of expertise in neurology and gastrointestinal diseases, as well as oncology. The company is also expanding research into new frontier areas in order to establish future specialty fields. In the fiscal year ended March 31, 2004, research and development spending totaled 69.0 billion yen or 18.3% of consolidated net sales.

MultiCell CEO, Jerry Newmin, said, "We are gratified with this order from such a respected firm and to see XenoTech's international marketing efforts begin to bear fruit. We believe other big pharmas will need to follow suit for competitive reasons, and several are now evaluating our cell lines for use in drug discovery." He added, "It is our hope that the use of MultiCell's immortalized hepatocytes in testing drug candidates will help prevent the long-term expense and possible danger to patients of recalled drugs."

MultiCell Technologies, Inc. provides non-tumorigenic functional hepatic (liver) cells and cell lines to pharmaceutical companies for induction studies and toxicity screening for drug discovery. Hepatocytes express drug-metabolizing enzymes which bio-transform drugs or substances ingested into the body. Drug failures or FDA rejections due to hepatotoxicity and/or drug-drug interactions now cost the pharmaceutical industry an estimated $2 billion each year. It costs about $900 million to develop and test a new medicine.

Dr. Andrew Parkinson, XenoTech CEO, stated, "With the challenges presented in shipping freshly-prepared hepatocytes overseas, we are pleased that this major pharmaceutical company is making such a firm commitment to MultiCell's novel cell line. This is a milestone for gaining industry acceptance of this new technology in drug discovery and development research applications worldwide."

MultiCell's cellular product expertise also enables production of biologics for use in diagnostic and therapeutic applications, as well as production of liver-derived therapeutic proteins. The Company's majority-owned Xenogenics subsidiary owns all rights to the patented Sybiol(TM) synthetic bio-liver device. MultiCell's immortalized hepatocytes are hoped to operate optimally with any working bio-liver device and thus facilitate serving as a bridge for patients waiting for liver transplants, and as a treatment option for chronic liver disease.

MultiCell's headquarters are at 55 Access Road, Suite 700, in Warwick, R.I. For more information about MultiCell and its Xenogenics subsidiary, call 401-738-7560 or see www.multicelltechnologies.com. For pricing and delivery information for 6- to 96-well plates or vials, contact MultiCell's marketing and manufacturing licensee, XenoTech, LLC of Lenexa, Kan., telephone 913-GET-P450.

The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.



--------------------------------------------------------------------------------
Contact:
MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560



--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.
biz.yahoo.com

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)


To: Shawn Donahue who wrote (25)11/6/2004 10:24:43 PM
From: Sidney Reilly
   of 228
 
Oh oh it's shawn. Will you chase me off this thread too? <g> Just checking out MUCL.

Things are looking up for SRAM after a few bad months. Do you still hold SRAM?

Share Recommend | Keep | Reply | Mark as Last Read


From: Shawn Donahue11/15/2004 12:24:20 PM
   of 228
 
MultiCell Licensee Markets Immortalized Cell Lines at AAPS
Monday November 15, 11:00 am ET


WARWICK, R.I.--(BUSINESS WIRE)--Nov. 15, 2004--MultiCell Technologies, Inc. (OTCBB:MUCL - News), leading supplier of functional non-tumorigenic immortalized human hepatocyte lines Fa2n-4 and EA1C-35, announced that XenoTech LLC, its marketing and manufacturing licensee, presented MultiCell's cells at the American Association of Pharmaceutical Scientists meeting November 7th - 11th in Baltimore, MD. This year's annual meeting was the highest-attended AAPS event ever, with over 4,500 registrations and over 450 exhibitors.
The AAPS conference covers a broad variety of interests in addition to drug development, which is the current target market for the Fa2N-4 cells. A XenoTech spokesperson indicated that XenoTech's new exhibit featuring the immortalized hepatocytes was well received and the number of leads generated was significantly higher than expected.

Drug induced liver injury is now the leading cause of liver failure in the U.S. As concerns about drug-drug interactions and toxicity rise, labor and animal costs rise. High throughput screening using MultiCell's hepatocytes is expected to become a preferred alternative. MultiCell's immortalized human hepatocyte lines closely resemble primary human liver cells in morphology and function. Thus they may save years of time and millions of dollars during preclinical drug discovery, development and testing stages, eliminating the problem of supply and variability that restrict the use of harvested human liver cells for enzyme induction, cellular toxicity assays and other in vitro screening. Hepatocytes express drug-metabolizing enzymes that biotransform drugs or substances ingested into the body, so they help predict the effect of a compound on human livers. MultiCell's cell lines are quite sensitive to compounds that alter the expression of CYP3A4, an essential feature of in vitro model systems when studying drug-drug interactions.

For pricing and delivery information of 6 to 96 well plates or vials, contact XenoTech LLC of Lenexa, KS, telephone 913-GET-P450 or see www.xenotechllc.com.

MultiCell is at 55 Access Road, Suite 700, in Warwick, Rhode Island. For information about MultiCell and its majority-owned Xenogenics subsidiary, which owns all rights to the Sybiol(TM) synthetic bio-liver device, call 401-738-7560 or see www.multicelltech.com.

The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.



--------------------------------------------------------------------------------
Contact:
MultiCell Technologies, Inc.
Jerry Newmin, 401-738-7560



--------------------------------------------------------------------------------
Source: MultiCell Technologies, Inc.
biz.yahoo.com

Share Recommend | Keep | Reply | Mark as Last Read


To: EACarl who wrote (23)11/29/2004 8:23:17 AM
From: Tradenride
   of 228
 
EAC, you know as well as everyone here that MAY means CLOSE TO if not all.

Share Recommend | Keep | Reply | Mark as Last Read


From: Shawn Donahue1/11/2005 6:14:46 PM
   of 228
 
Form 8-K for MULTICELL TECHNOLOGIES INC.

11-Jan-2005

Other Events


ITEM 8.01. OTHER EVENTS

On November 17, 2000, MultiCell Technologies, Inc.(the Company) entered into a $500,000 loan agreement with Lexicor Medical Technologies, Inc. (Lexicor). The amount of the loan was increased by $50,000 on February 20, 2001 and $50,000 on March 7, 2001. Interest was accrued at ten percent (10%) per year payable quarterly. Lexicor paid all quarterly payments when due throughout the term of the note. Under the terms of the note, if the note was not paid in full on May 31, 2001 the term of the loan was automatically extended until January 2, 2005. Failure of Lexicor to pay the note when due or any default by Lexicor would have caused Lexicor to issue common shares to the Company equal to 51% of the issued and outstanding shares of Lexicor. The note was also convertible into Lexicor common stock at a per share price of $6.00 per share. On December 30, 2004 Lexicor wired $605,000 as payment in full along with accrued interest to an escrow account for the Company. The funds were released from the escrow account to the Company on January 7, 2005.

biz.yahoo.com

Share Recommend | Keep | Reply | Mark as Last Read | Read Replies (1)
Previous 10 | Next 10 

Copyright © 1995-2014 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.